Trends in IVC Reconstruction Show High Patency and Survival

IVC reconstruction during oncologic resections is safe, with robust mid-term outcomes.

80 patients treated; 94%+ primary patency at 2 years.
30-day survival rate was 96.3%, with 2- and 3-year survival at 76.8%.

Most thrombosis occurrences tied to tumor recurrence or technical issues.

Consider this technique in high-volume centers for complex oncologic cases.

Journal Article by Furtado Neves PJ, Simioni A (…) Malgor RD et 5 al. in J Am Coll Surg

read the whole article in J Am Coll Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Ann Surg Oncol2 Nov 2026

Pancreatic ductoscopy guides tissue preservation

In two older patients having robotic surgery for a pancreatic growth, ductoscopy and checks of the cut edge let surgeons leave the remaining pancreas in place.

HPB & Spleen30 Oct 2026

Intrahepatic cholangiocarcinoma has more options

Resection remains central, but care now includes preoperative therapy, liver-directed treatments and drugs matched to tumor changes.

Ann Surg Oncol29 Oct 2026

Pancreatic cancer: longer survival with combined treatment

For locally advanced pancreatic cancer, cryoablation plus drug treatment was linked to longer median survival than drug treatment alone, but the result does not prove benefit.

All papers in HPB & Spleen →